CNBC
By Berkeley Lovelace Jr
July 13, 2021
Johnson & Johnson and AstraZeneca are conducting early stage research into whether potential modifications of their Covid-19 vaccines could reduce or eliminate the risk of rare, but serious, blood clots associated with the shots.
The blood clotting issue, which some scientists are calling vaccine-induced immune thrombotic thrombocytopenia, or VITT, has been linked to both shots. Scientists have been discovering clues into how the clots form, boosting hopes of possibly reengineering the shots, a person familiar with the matter told CNBC.